Journal Logo

Simultaneous Sessions II: Improvements in MDS treatment

S839 PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

Navada, S.C. MD1; Garcia-Manero, G. MD2; Atallah, E. MD3; Rajeh, M.N. MD4; Shammo, J.M. MD5; Griffiths, E.A. MD6; Khaled, S.K. MD7; Dakhil, S.R. MD8; Young, D.E. MD9; Odchimar-Reissig, R. RN1; Demakos, E.P. RN1; Alvarado Valero, Y. MD2; Ohanian, M.N. DO2; Pemmaraju, N. MD2; John, R.B. MSN2; Zbyszewski, P.S. MBA10; Maniar, M. PhD10; Petrone, M.E. MD, MPH10; Woodman, R.C. MD10; Fruchtman, S.M. MD10; Silverman, L.R. MD1

Author Information
doi: 10.1097/01.HS9.0000561636.42487.8d
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.